VPT:CC - Ventripoint Partners with Fournel Advisory
(TheNewswire)
Toronto, Ontario – TheNewswire - June 17, 2025 – VentripointDiagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased toannounce that it has entered into an advisory agreement with FournelAdvisory (“Fournel”) to provide the Company with financialadvisory, business development and M&A services for one year toaccelerate the commercialization of Ventripoint’s AI-powered,heart-scanning technology. Under the terms of the agreement theCompany shall pay a cash fee and provide Fournel an option to purchase265,000 common shares at the market price on June 11, 2025 of $0.11,subject to TSX Venture Exchange approval.
Strategic Advisory
Fournel Advisory is a Paris-based consulting firm dedicated tosupporting entrepreneurs and business leaders across Small and Mid-Capmarkets. Since 2013, Fournel has specialized in M&A advisory,fundraising, and special situations, both in France andinternationally. With a strong focus on the Healthcare and LifeSciences sectors, it brings tailored, high-impact advice to clients atevery stage of their growth. It is supported by the "FournelAdvisory Life Sciences" (FALS) Scientific Committee - referred toas its KOL network - comprising leading figures from academia,biotechnology, life sciences, and finance worldwide. This uniqueresource allows Fournel to identify new trends, provide strategicinsights into value creation, and support critical fundraisingdocumentation.
Fournel Advisory has completed more than 50 transactions since itsinception and currently supports around 30 active mandates, rangingfrom biotech and medtech to pharma and medical devices. It isstage-agnostic, helping startups and growth companies alike, fromearly development through late-stage expansion. 70% of Fournel’sclient base and investor relationships are international, especiallyacross North America (U.S. and Canada) and Europe.
Founded by Pierre-Jean Esmieu Fournel, a former HEC graduate andInvestment Banker at Société Générale (New York, South Africa,UK), and later CFO and VP of Business Development at Ethypharm, wherehe led a $135M fundraising in a turnaround situation, Fournel Advisorywas born out of firsthand experience in the challenges - and thepromise - of the biotech and pharma worlds. Fournel is passionateabout enabling pioneering companies to achieve their ambitions byproviding financial expertise, strategic advice, and access to aglobal network of investors and partners.
“ Ventripoint is excited by theopportunity to work with the Fournel Advisory team ” statedVentripoint President and CEO Hugh MacNaught. “Their experience in the Healthcaresector and extensive network will be invaluable in acceleratingVentripoint’s growth and supporting the true value of theCompany.”
Commenting on the agreement,Pierre-Jean Esmieu Fournel said: “ We are delighted to partner with Ventripoint, a company at theintersection of AI and cardiac imaging, whose technology has thepotential to reshape cardiovascular diagnostics. At Fournel Advisory,we strongly believe in thepower of healthcare innovation, and we are committed to leveraging ourglobal network and financial expertise to support Ventripoint’sgrowth and long-term success. ”
With its proprietary VMS+™ platform, Ventripoint is revolutionizingcardiac diagnostics by delivering a powerful AI-driven solution thatenhances echocardiography and serves as an affordable and moreaccessible alternative to traditional MRI scans. Following recentregulatory milestones, Ventripoint is now primed to expand itspresence in key markets and drive widespread adoption.
For further information, pleasecontact:
Hugh MacNaught
(604) 671-4201
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.